Phenotypes associated with this allele

• Allele Symbol: Mmp9^tm1Tvu
• Allele Name: targeted mutation 1, Thiennu H Vu
• Allele ID: MGI:1932294
• Summary: 33 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Mmp9^tm1Tvu/Mmp9^tm1Tvu	129S6/SvEvTac-Mmp9^tm1Tvu	MGI:3785291
hm2	Mmp9^tm1Tvu/Mmp9^tm1Tvu	B6.129S6-Mmp9^tm1Tvu	MGI:4365602
hm3	Mmp9^tm1Tvu/Mmp9^tm1Tvu	C3N.129S6-Mmp9^tm1Tvu	MGI:4367720
hm4	Mmp9^tm1Tvu/Mmp9^tm1Tvu	either: (involves: 129S6/SvEvTac * Black Swiss) or (involves: 129S6/SvEvTac * CD-1)	MGI:2175116
hm5	Mmp9^tm1Tvu/Mmp9^tm1Tvu	either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6J)	MGI:3652556
hm6	Mmp9^tm1Tvu/Mmp9^tm1Tvu	either: FVB.129S6-Mmp9^tm1Tvu or (involves: 129S6/SvEvTac)	MGI:3652546
hm7	Mmp9^tm1Tvu/Mmp9^tm1Tvu	FVB.129S6-Mmp9^tm1Tvu	MGI:3656012
hm8	Mmp9^tm1Tvu/Mmp9^tm1Tvu	FVB.Cg-Mmp9^tm1Tvu/J	MGI:4367701
hm9	Mmp9^tm1Tvu/Mmp9^tm1Tvu	involves: 129/Sv * 129S6/SvEvTac	MGI:4365580
hm10	Mmp9^tm1Tvu/Mmp9^tm1Tvu	involves: 129S6/SvEvTac	MGI:3652578
hm11	Mmp9^tm1Tvu/Mmp9^tm1Tvu	involves: 129S6/SvEvTac * C57BL/6	MGI:4367607
hm12	Mmp9^tm1Tvu/Mmp9^tm1Tvu	involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac	MGI:4367696
hm13	Mmp9^tm1Tvu/Mmp9^tm1Tvu	involves: 129S6/SvEvTac * C57BL/6J	MGI:3652586
hm14	Mmp9^tm1Tvu/Mmp9^tm1Tvu	involves: 129S6/SvEvTac * CD-1	MGI:4367273
hm15	Mmp9^tm1Tvu/Mmp9^tm1Tvu	involves: 129S6/SvEvTac * FVB/N	MGI:4367616
cx16	Dmd^mdx/Dmd^mdx Mmp9^tm1Tvu/Mmp9^tm1Tvu	B10.Cg-Mmp9^tm1Tvu Dmd^mdx	MGI:4367735
cx17	Dmd^mdx/Dmd^mdx Mmp9^tm1Tvu/Mmp9^+	B10.Cg-Mmp9^tm1Tvu Dmd^mdx	MGI:4367736
cx18	Mmp9^tm1Tvu/Mmp9^tm1Tvu Rag2^tm1Fwa/Rag2^tm1Fwa	B6.129S-Rag2^tm1Fwa Mmp9^tm1Tvu	MGI:4365603
cx19	Mmp2^tm1Ito/Mmp2^tm1Ito Mmp9^tm1Tvu/Mmp9^tm1Tvu	involves: 129P2/OlaHsd * 129S6/SvEvTac	MGI:4367346
cx20	Apoe^tm1Unc/Apoe^tm1Unc Mmp9^tm1Tvu/Mmp9^tm1Tvu	involves: 129P2/OlaHsd * 129S6/SvEvTac	MGI:4367614
cx21	Mmp9^tm1Tvu/Mmp9^tm1Tvu Sftpd^tm1Jhf/Sftpd^tm1Jhf	involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * FVB/N	MGI:4367694
cx22	Mmp9^tm1Tvu/Mmp9^tm1Tvu Rag2^tm1Fwa/Rag2^tm1Fwa	involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6 * FVB/N	MGI:4367710
cx23	Col4a3^tm1Jhm/Col4a3^tm1Jhm Mmp9^tm1Tvu/Mmp9^tm1Tvu	involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ	MGI:3510654
cx24	Hspg2^tm1Ref/Hspg2^tm1Ref Mmp9^tm1Tvu/Mmp9^tm1Tvu	involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ	MGI:3590209
cx25	Mmp13^tm1.1Werb/Mmp13^tm1.1Werb Mmp9^tm1Tvu/Mmp9^tm1Tvu	involves: 129S2/SvPas * 129S6/SvEvTac	MGI:3522359
cx26	Mmp9^tm1Tvu/Mmp9^tm1Tvu Timp1^tm1Pds/Timp1^tm1Pds	involves: 129S4/SvJae * 129S6/SvEvTac	MGI:3525489
cx27	Mmp12^tm1Sds/Mmp12^tm1Sds Mmp9^tm1Tvu/Mmp9^tm1Tvu	involves: 129S6/SvEvTac * 129X1/SvJ	MGI:3652810
cx28	Mmp8^tm1Otin/Mmp8^tm1Otin Mmp9^tm1Tvu/Mmp9^tm1Tvu	involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6	MGI:3785292
cx29	Mmp9^tm1Tvu/Mmp9^tm1Tvu Tg(SOD1*G93A)1Gur/0	involves: 129S6/SvEvTac * C57BL/6 * CD-1 * SJL	MGI:4367704
cx30	Mmp9^tm1Tvu/Mmp9^tm1Tvu Tg(KRT14-HPV16)wt1Dh/0	involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * FVB/N	MGI:4367274
cx31	Mmp9^tm1Tvu/Mmp9^tm1Tvu Tg(MMTV-PyVT)634Mul/0	involves: 129S6/SvEvTac * C57BL/6 * FVB/N	MGI:4367707
cx32	Mmp13^tm1Jdar/Mmp13^tm1Jdar Mmp9^tm1Tvu/Mmp9^tm1Tvu	involves: 129S6/SvEvTac * C57BL/6J * FVB/N	MGI:4367723
cx33	Mmp9^tm1Tvu/Mmp9^tm1Tvu Tg(MMTV-PyVT)634Mul/0	involves: 129S6/SvEvTac * FVB/N	MGI:4367708

Genotype
MGI:3785291

hm1

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: 129S6/SvEvTac-Mmp9^tm1Tvu

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

immune system phenotype ( J:113463 )

N • mice exhibit a normal local Shwartman response namely thrombohemorrhagic vasculitis

Genotype
MGI:4365602

hm2

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: B6.129S6-Mmp9^tm1Tvu

neoplasm

abnormal tumor morphology ( J:105098 )

• injected A549 cells exhibit an increase in early apoptosis compared to in wild-type mice

decreased tumor incidence ( J:105098 )

• mice injected with Lewis lung carcinoma or A549 cells exhibit a decrease in tumors compared with similarly treated wild-type mice

Genotype
MGI:4367720

hm3

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: C3N.129S6-Mmp9^tm1Tvu

immune system

joint inflammation ( J:150311 )

• in B. burgdorferi-infected mice compared with similarly treated wild-type mice

decreased susceptibility to induced arthritis ( J:150311 )

• B. burgdorferi-infected mice exhibit reduced arthritis compared with similarly treated wild-type mice

• however, spirochete numbers in the joint are normal

decreased susceptibility to bacterial infection ( J:150311 )

• mice infected with Borrelia burgdorferi exhibit less ankle swelling, joint inflammation, and arthritis than similarly treated wild-type mice

• however, mice exhibit normal development of carditis when infected with B. burgdorferi

skeleton

joint swelling ( J:150311 )

• in B. burgdorferi-infected mice compared with similarly treated wild-type mice

joint inflammation ( J:150311 )

• in B. burgdorferi-infected mice compared with similarly treated wild-type mice

decreased susceptibility to induced arthritis ( J:150311 )

• B. burgdorferi-infected mice exhibit reduced arthritis compared with similarly treated wild-type mice

• however, spirochete numbers in the joint are normal

homeostasis/metabolism

joint swelling ( J:150311 )

• in B. burgdorferi-infected mice compared with similarly treated wild-type mice

Genotype
MGI:2175116

hm4

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: either: (involves: 129S6/SvEvTac * Black Swiss) or (involves: 129S6/SvEvTac * CD-1)

skeleton

abnormal metatarsal bone morphology ( J:47297 )

• hypertrophic cartilage zone in the metatarsals is about twice that of wild-type at birth and becomes more pronounced with growth so that by 3 weeks, it is 6-8 times as long

abnormal long bone epiphyseal plate morphology ( J:47297 )

• abnormal growth plate development, however after 3 weeks of age, aberrant apoptosis, vascularization, and ossification compensate to remodel the enlarged growth plate and ultimately produce an axial skeleton of normal appearance except for the shorter long bones

abnormal long bone hypertrophic chondrocyte zone ( J:47297 )

• ectopic areas of ossification begin to appear within the hypertrophic zone at 4 weeks of age

• apoptosis of hypertrophic chondrocytes is delayed

• by 3 weeks of age, when the hypertrophic zone is lengthened, aberrant apoptosis begins in the middle of the hypertrophic cartilage and is seen around the areas of ossification throughout the hypertrophic zone at 4 weeks

increased width of hypertrophic chondrocyte zone ( J:47297 )

• exhibit lengthened zone of hypertrophic cartilage with no difference in the reserve or proliferating zones

decreased length of long bones ( J:47297 )

• long bones are about 10% shorter than in wild-type

short femur ( J:47297 )

short tibia ( J:47297 )

abnormal trabecular bone morphology ( J:47297 )

• area of metaphyseal trabecular bone is shorter

osteopetrosis ( J:47297 )

• ectopic areas of ossification begin to appear within the hypertrophic zone at 4 weeks of age and the ectopic ossification proceeds rapidly so that in some bones the entire zone of hypertrophic cartilage is ossified, leading to a large area of trabecular bone, however this is resolved with subsequent remodeling so that by 8 weeks, bones appear normal

delayed bone ossification ( J:47297 )

• secondary (epiphyseal) ossification sites are delayed until 2.5 weeks of age, however, by 3 weeks of age, these sites are completely ossified as in wild-type

limbs/digits/tail

short femur ( J:47297 )

short tibia ( J:47297 )

abnormal metatarsal bone morphology ( J:47297 )

• hypertrophic cartilage zone in the metatarsals is about twice that of wild-type at birth and becomes more pronounced with growth so that by 3 weeks, it is 6-8 times as long

Genotype
MGI:3652556

hm5

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * C57BL/6J)

cardiovascular system

abnormal angiogenesis ( J:95880 )

• exhibit reduced angiogenic response to peripheral leg ischemia; do not observe an increase in capillary density and see reduced capillary perfusion capacity and fewer points of capillary intersections (decreased branching) after ischemia

Genotype
MGI:3652546

hm6

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: either: FVB.129S6-Mmp9^tm1Tvu or (involves: 129S6/SvEvTac)

cardiovascular system

abnormal response to cardiac infarction ( J:68211 )

• exhibit less left ventricular dilation after experimental myocardial infarction and show less collagen accumulation in the infracted area than seen in wild-type

homeostasis/metabolism

abnormal response to cardiac infarction ( J:68211 )

• exhibit less left ventricular dilation after experimental myocardial infarction and show less collagen accumulation in the infracted area than seen in wild-type

Genotype
MGI:3656012

hm7

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: FVB.129S6-Mmp9^tm1Tvu

mortality/aging

decreased susceptibility to xenobiotic induced morbidity/mortality ( J:104644 )

• DSS-treated mice exhibit no mortality unlike similarly treated wild-type mice

• however, mice exhibit normal mortality in response to Salmonella typhimurium-induced systemic sepsis

cardiovascular system

abnormal physiological neovascularization ( J:104786 )

• exhibit increased neovascularization post myocardial infarction, as shown by increased total vessel density and normalized vessel distribution between subendo- and epicardial regions relative to wild-type after coronary artery ligation

increased angiogenesis ( J:104786 )

• exhibit an increased angiogenic potential after myocardial infarction, as shown by the presence of newly formed vessels in the infarct region

increased heart ventricle muscle contractility ( J:104786 )

• exhibit higher end-systolic pressure and dP/dt_max than wild-type after myocardial infarction, despite similar infarct sizes

abnormal response to cardiac infarction ( J:104786 )

• exhibit an increased infarct-to-septal wall thickness ratio, attenuated wall thinning, improved left ventricular function, and reduced peak macrophage infiltration into the infarct zone relative to wild-type after myocardial infarction

immune system

immune system phenotype ( J:104644 )

N

decreased susceptibility to induced colitis ( J:104644 )

• DSS-treated mice exhibit no weight loss, mortality or lymphocyte accumulation in the colon, reduced neutrophil accumulation, colon shortening, intestinal inflammation, and intestinal injury, and fewer incidence of diarrhea and bleeding compared with similarly treated wild-type mice

• mice treated orally with Salmonella typhimurium to induce colitis exhibit reduced weight loss and destruction of crypt architecture compared with similarly treated wild-type mice

abnormal neutrophil physiology ( J:104644 )

• neutrophil chemotatic response to fMLP is greater than for wild-type cells

• polymononuclear cell migration through Matri-gel-coated membrane in response to fMLP is greater compared with similarly treated wild-type cells

homeostasis/metabolism

abnormal response to cardiac infarction ( J:104786 )

• exhibit an increased infarct-to-septal wall thickness ratio, attenuated wall thinning, improved left ventricular function, and reduced peak macrophage infiltration into the infarct zone relative to wild-type after myocardial infarction

decreased susceptibility to xenobiotic induced morbidity/mortality ( J:104644 )

• DSS-treated mice exhibit no mortality unlike similarly treated wild-type mice

• however, mice exhibit normal mortality in response to Salmonella typhimurium-induced systemic sepsis

muscle

increased heart ventricle muscle contractility ( J:104786 )

• exhibit higher end-systolic pressure and dP/dt_max than wild-type after myocardial infarction, despite similar infarct sizes

digestive/alimentary system

decreased susceptibility to induced colitis ( J:104644 )

• DSS-treated mice exhibit no weight loss, mortality or lymphocyte accumulation in the colon, reduced neutrophil accumulation, colon shortening, intestinal inflammation, and intestinal injury, and fewer incidence of diarrhea and bleeding compared with similarly treated wild-type mice

• mice treated orally with Salmonella typhimurium to induce colitis exhibit reduced weight loss and destruction of crypt architecture compared with similarly treated wild-type mice

hematopoietic system

abnormal neutrophil physiology ( J:104644 )

• neutrophil chemotatic response to fMLP is greater than for wild-type cells

• polymononuclear cell migration through Matri-gel-coated membrane in response to fMLP is greater compared with similarly treated wild-type cells

Genotype
MGI:4367701

hm8

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: FVB.Cg-Mmp9^tm1Tvu/J

mortality/aging

decreased susceptibility to Flaviviridae infection induced morbidity/mortality ( J:153406 )

• mice infected with West Nile virus exhibit decreased mortality compared with similarly treated wild-type mice

• however, mice exhibit a normal survival when injected intracerebrally with West Nile virus

cellular

abnormal intestinal goblet cell morphology ( J:128322 )

• mice exhibit an increased in the number of intestinal goblet cells compared to in wild-type mice

• however, the number of goblet cells per crypt is normal

immune system

decreased susceptibility to Flaviviridae infection ( J:153406 )

• mice infected with West Nile virus exhibit decreased mortality, brain viral load, CD45+ leukocyte infiltration into brain tissue, and blood brain barrier permeability compared with similarly treated wild-type mice

• however, mice exhibit a normal response to West Nile virus infection when injected intracerebrally with the virus

decreased susceptibility to Flaviviridae infection induced morbidity/mortality ( J:153406 )

• mice infected with West Nile virus exhibit decreased mortality compared with similarly treated wild-type mice

• however, mice exhibit a normal survival when injected intracerebrally with West Nile virus

digestive/alimentary system

abnormal intestinal goblet cell morphology ( J:128322 )

• mice exhibit an increased in the number of intestinal goblet cells compared to in wild-type mice

• however, the number of goblet cells per crypt is normal

behavior/neurological

hypoalgesia ( J:133660 )

• 3 days after spinal nerve ligation, mice exhibit less spontaneous pain and early phase mechanical allodynia compared with similarly treated wild-type mice

• however, mice exhibit normal neuropathic pain by 10 days following spinal nerve ligation

homeostasis/metabolism

abnormal response/metabolism to endogenous compounds ( J:147593 )

• mice treated with tumor necrosis factor-related weak inducer of apoptosis (TWEAK or Tnfsf12) exhibit increased body and muscle weight, intact basement membrane, and reduced myopathy, clustering of inflammatory cells, and number of necrotic fibers in the muscle compared with similarly treated wild-type mice

decreased susceptibility to injury ( J:133660 , J:148923 )

• 3 days after spinal nerve ligation, mice exhibit less spontaneous pain and early phase mechanical allodynia compared with similarly treated wild-type mice (J:133660)

• however, mice exhibit normal neuropathic pain by 10 days following spinal nerve ligation (J:133660)

• following hepatic ischemia and reperfusion, hepatic apoptosis is decreased compared to in similarly treated wild-type mice (J:148923)

cardiovascular system

enhanced blood-brain barrier function ( J:153406 )

• mice infected with West Nile virus exhibit decreased blood brain barrier permeability compared with similarly treated wild-type mice

nervous system

enhanced blood-brain barrier function ( J:153406 )

• mice infected with West Nile virus exhibit decreased blood brain barrier permeability compared with similarly treated wild-type mice

growth/size/body

increased body weight ( J:147593 )

• in tumor necrosis factor-related weak inducer of apoptosis (TWEAK or Tnfsf12)-treated mice compared with similarly treated wild-type mice

muscle

increased tibialis anterior weight ( J:147593 )

• the weight of the tibialis anterior in mice treated with Tnfsf12-treated mice is greater than in similarly treated wild-type mice

limbs/digits/tail

increased tibialis anterior weight ( J:147593 )

• the weight of the tibialis anterior in mice treated with Tnfsf12-treated mice is greater than in similarly treated wild-type mice

Genotype
MGI:4365580

hm9

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: involves: 129/Sv * 129S6/SvEvTac

homeostasis/metabolism

decreased circulating interleukin-10 level ( J:55723 )

• DNFB-sensitized and challenged mice have lower IL10 levels compared with similarly treated wild-type mice despite normal capacity of spleen cells to produce IL10 after LPS exposure

immune system

decreased circulating interleukin-10 level ( J:55723 )

• DNFB-sensitized and challenged mice have lower IL10 levels compared with similarly treated wild-type mice despite normal capacity of spleen cells to produce IL10 after LPS exposure

increased susceptibility to type IV hypersensitivity reaction ( J:55723 )

• DNFB-sensitized and challenged mice exhibit a prolonged response and delayed resolution of inflammation compared with similarly treated wild-type mice

• however, resolution of phenol elicited inflammation is normal

Genotype
MGI:3652578

hm10

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: involves: 129S6/SvEvTac

mortality/aging

increased susceptibility to Picornaviridae infection induced morbidity/mortality ( J:148442 )

• CVB3-infected mice exhibit increased morbidity compared with similarly treated wild-type mice

homeostasis/metabolism

abnormal vascular wound healing ( J:109006 )

• exhibit attenuated arterial remodeling in response to vascular injury (ligation of carotid artery) compared to wild-type, with decreases in late lumen loss, neointimal thickening, and migration of smooth muscle cells into the neointima and an accumulation of interstitial collagen

increased circulating interferon-beta level ( J:148442 )

• in CVB3-infected mice compared to in similarly treated wild-type mice

increased circulating interferon-gamma level ( J:148442 )

• in CVB3-infected mice compared to in similarly treated wild-type mice

abnormal chemokine level ( J:84293 )

• ovalbumin sensitized and exposed mice exhibit reduced CCL17 protein levels in the bronchoalveolar lavage fluid compared with similarly treated wild-type mice

decreased physiological sensitivity to xenobiotic ( J:84293 )

• mice sensitized and exposed to ovalbumin fail to exhibit the airway inflammation observed in similarly treated wild-type mice

• mice sensitized and exposed to ovalbumin exhibit impaired ovalbumin-IgE production compared with similarly treated wild-type mice

• following ovalbumin treatment, the numbers of dendritic cell in the bronchoalveolar lavage fluid and airway walls does not increase as much as in similarly treated wild-type mice

• ovalbumin sensitized and exposed mice exhibit reduced CCL17 protein levels in the bronchoalveolar lavage fluid compared with similarly treated wild-type mice

decreased susceptibility to injury ( J:79422 , J:91478 , J:114188 )

• mice are resistant to traumatic brain injury compared with similarly treated wild-type mice with smaller traumatic lesion volumes (J:79422)

• mice are resistant to the pathogenic activity of anti-mBP180 (Col17a1) antibodies that induce subepidermal blistering in wild-type mice (J:91478)

• however, mice reconstituted with wild-type neutrophils exhibit normal response to anti-Col17a1 antibodies (J:91478)

• following IgG-induction of acute lung injury, mice exhibit reduced lung injury, decreased BALF protein leakage, and perivascular edema compared with similarly treated wild-type mice (J:114188)

• however, the number of macrophages and neutrophils recruited to the lungs is normal in mice with IgG-induced acute lung injury (J:114188)

immune system

myocarditis ( J:148442 )

• CVB3-infected mice exhibit an increase in T cell infiltration in the heart compared with similarly treated wild-type mice

decreased dendritic cell number ( J:84293 )

• following ovalbumin treatment, the numbers of dendritic cell in the bronchoalveolar lavage fluid and airway walls does not increase as much as in similarly treated wild-type mice

decreased IgE level ( J:84293 )

• mice sensitized and exposed to ovalbumin exhibit impaired ovalbumin-IgE production compared with similarly treated wild-type mice

increased circulating interferon-beta level ( J:148442 )

• in CVB3-infected mice compared to in similarly treated wild-type mice

increased circulating interferon-gamma level ( J:148442 )

• in CVB3-infected mice compared to in similarly treated wild-type mice

abnormal chemokine level ( J:84293 )

• ovalbumin sensitized and exposed mice exhibit reduced CCL17 protein levels in the bronchoalveolar lavage fluid compared with similarly treated wild-type mice

abnormal dendritic cell physiology ( J:84293 )

• in vitro, chemotaxis of dendritic cells in response to CCL5 (RANTES) and CCL20 (MIP-3alpha) is impaired compared with similarly treated wild-type cells

• however, homing of dendritic cells from airways to lymph nodes in mice is normal

abnormal Langerhans cell physiology ( J:76157 )

• migration of Langerhans cells is impaired compared to in wild-type mice

• however, maturation of Langerhans cells is normal

decreased inflammatory response ( J:84293 )

• mice sensitized and exposed to ovalbumin fail to exhibit the airway inflammation observed in similarly treated wild-type mice

increased susceptibility to Picornaviridae infection ( J:148442 )

• Coxsackievirus B3 (CVB3)-infected mice exhibit increased morbidity, viral load, serum IFN-gamma and IFN-beta, left ventricular posterior wall and interventricular septum thickness, and cardiac injury as determined by increased myocytolysis, calcification, and cellular infiltrate and decreased ejection fraction and E wave compared with similarly treated wild-type mice

increased susceptibility to Picornaviridae infection induced morbidity/mortality ( J:148442 )

• CVB3-infected mice exhibit increased morbidity compared with similarly treated wild-type mice

cardiovascular system

abnormal induced retina neovascularization ( J:113620 )

• mice exhibit 45% less ischemia-induced retinal neovascularization compared with similarly treated wild-type mice

thick interventricular septum ( J:148442 )

• CVB3-infected mice exhibit increased interventricular septum thickness compared with similarly treated wild-type mice

increased heart left ventricle posterior wall thickness ( J:148442 )

• CVB3-infected mice exhibit increased left ventricular posterior wall thickness compared with similarly treated wild-type mice

cardiac fibrosis ( J:148442 )

• in CVB3-infected mice compared to in similarly treated wild-type mice

increased susceptibility to dystrophic cardiac calcinosis ( J:148442 )

• in CVB3-infected mice compared to in similarly treated wild-type mice

decreased susceptibility to induced aneurysm formation ( J:62760 )

• following induction of aortic aneurysm with elastase, mice develop fewer aneurysms with less of an increase in aortic diameter compared with similarly treated wild-type mice

• however, mice reconstituted with wild-type bone marrow exhibit normal susceptibility to elastase-induced aortic aneurysms

decreased cardiac muscle contractility ( J:148442 )

• on day 9 post-infection in CVB3-infected mice compared to in similarly treated wild-type mice

abnormal impulse conducting system conduction ( J:148442 )

• on days 3 and 9, CVB3-infected mice exhibit decreased E wave compared with similarly treated wild-type mice

abnormal myocardial fiber physiology ( J:148442 )

• myocytolysis is increased in CVB3-infected mice compared to in similarly treated wild-type mice

abnormal vascular smooth muscle physiology ( J:109006 )

• isolated aortic smooth muscle cells show decreased migration and capacity to contract collagen in vitro

abnormal vascular wound healing ( J:109006 )

• exhibit attenuated arterial remodeling in response to vascular injury (ligation of carotid artery) compared to wild-type, with decreases in late lumen loss, neointimal thickening, and migration of smooth muscle cells into the neointima and an accumulation of interstitial collagen

myocarditis ( J:148442 )

• CVB3-infected mice exhibit an increase in T cell infiltration in the heart compared with similarly treated wild-type mice

nervous system

decreased oligodendrocyte number ( J:105765 )

• exhibit a decrease in the number of mature oligondendrocytes at P10, however no differences in oligodendrocyte precursor cell numbers

abnormal myelination ( J:105765 )

• exhibit decreased myelination in the corpus callosum at P7 and P10, but not at P14, as evidenced by decreased MBP expression

muscle

decreased cardiac muscle contractility ( J:148442 )

• on day 9 post-infection in CVB3-infected mice compared to in similarly treated wild-type mice

abnormal vascular smooth muscle physiology ( J:109006 )

• isolated aortic smooth muscle cells show decreased migration and capacity to contract collagen in vitro

hematopoietic system

decreased dendritic cell number ( J:84293 )

• following ovalbumin treatment, the numbers of dendritic cell in the bronchoalveolar lavage fluid and airway walls does not increase as much as in similarly treated wild-type mice

decreased IgE level ( J:84293 )

• mice sensitized and exposed to ovalbumin exhibit impaired ovalbumin-IgE production compared with similarly treated wild-type mice

vision/eye

abnormal induced retina neovascularization ( J:113620 )

• mice exhibit 45% less ischemia-induced retinal neovascularization compared with similarly treated wild-type mice

Genotype
MGI:4367607

hm11

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6

immune system

increased T cell proliferation ( J:88065 )

• on day 24 hours in ovalbumin-treated wild-type mice compared with similarly treated wild-type mice

abnormal leukocyte morphology ( J:88065 )

increased eosinophil cell number ( J:88065 )

• on days 24 and 30, ovalbumin-treated mice exhibit an increase in the bronchoalveolar lavage and lung tissue eosinophil numbers compared with similarly treated wild-type mice

increased lymphocyte cell number ( J:88065 )

• ovalbumin-treated mice exhibit an increase in the bronchoalveolar lavage and lung tissue lymphocyte numbers compared with similarly treated wild-type mice

increased T-helper 2 cell number ( J:88065 )

• on day 24, ovalbumin-treated mice exhibit an increased in Th2 helper cells in the bronchoalveolar lavage compared with similarly treated wild-type mice

increased macrophage cell number ( J:88065 )

• ovalbumin-treated mice exhibit an increase in the bronchoalveolar lavage and lung tissue macrophage cell numbers compared with similarly treated wild-type mice

increased monocyte cell number ( J:88065 )

• ovalbumin-treated mice exhibit an increase in the bronchoalveolar lavage and lung tissue monocyte numbers compared with similarly treated wild-type mice

increased IgE level ( J:88065 )

• ovalbumin-treated mice exhibit increased ovalbumin-IgE compared with similarly treated wild-type mice

abnormal chemokine level ( J:88065 )

• on day 24, alum treated mice exhibit an increase in CCL22 in lung tissue compared with similarly treated wild-type mice

• on days 24 and 30, ovalbumin-treated mice exhibit increased CCL11 in the bronchoalveolar lavage compared with similarly treated wild-type mice

• on day 24, ovalbumin-treated mice exhibit an increase in bronchoalveolar lavage CCL22 compared with similarly treated wild-type mice

• on day 30, ovalbumin-treated mice exhibit an increase in lung tissue CCL22 compared with similarly treated wild-type mice

• however, mice exhibit normal levels of CCL2, CCL3, and CCL5 following ovalbumin treatment

abnormal cytokine secretion ( J:88065 )

decreased interferon-gamma secretion ( J:88065 )

• ovalbumin-treated mice exhibit decreased IFN-gamma in bronchoalveolar lavage compared with similarly treated wild-type mice

increased interferon-gamma secretion ( J:88065 )

• on day 24, T cells from alum-treated mice exhibit increased IFN-gamma secretion compared with cells from similarly treated wild-type mice

increased interleukin-13 secretion ( J:88065 )

• ovalbumin-treated mice exhibit increased IL13 in bronchoalveolar lavage and lung tissue compared with similarly treated wild-type mice

increased interleukin-4 secretion ( J:88065 )

• ovalbumin-treated mice exhibit increased IL4 in bronchoalveolar lavage and lung tissue compared with similarly treated wild-type mice

• on day 24, T cells from ovalbumin-treated mice exhibit increased IL4 secretion compared with cells from similarly treated wild-type mice

increased interleukin-5 secretion ( J:88065 )

• ovalbumin-treated mice exhibit increased IL5 in lung tissue compared with similarly treated wild-type mice

lung inflammation ( J:88065 )

• ovalbumin-treated mice exhibit increased lung inflammation with increased total cells, eosinophils, macrophages, lymphocytes, and monocytes in bronchoalveolar lavage and lung tissue compared with similarly treated wild-type mice

abnormal response to infection ( J:126519 )

• mice infected with Streptoccocus pneumoniae to in the right forebrain exhibit higher blood and spleen bacterial titers compared with similarly treated wild-type mice

• in experimental peritonitis, mice exhibit higher spleen bacterial titers compared with similarly treated wild-type mice

homeostasis/metabolism

abnormal chemokine level ( J:88065 )

• on day 24, alum treated mice exhibit an increase in CCL22 in lung tissue compared with similarly treated wild-type mice

• on days 24 and 30, ovalbumin-treated mice exhibit increased CCL11 in the bronchoalveolar lavage compared with similarly treated wild-type mice

• on day 24, ovalbumin-treated mice exhibit an increase in bronchoalveolar lavage CCL22 compared with similarly treated wild-type mice

• on day 30, ovalbumin-treated mice exhibit an increase in lung tissue CCL22 compared with similarly treated wild-type mice

• however, mice exhibit normal levels of CCL2, CCL3, and CCL5 following ovalbumin treatment

respiratory system

lung inflammation ( J:88065 )

• ovalbumin-treated mice exhibit increased lung inflammation with increased total cells, eosinophils, macrophages, lymphocytes, and monocytes in bronchoalveolar lavage and lung tissue compared with similarly treated wild-type mice

hematopoietic system

increased T cell proliferation ( J:88065 )

• on day 24 hours in ovalbumin-treated wild-type mice compared with similarly treated wild-type mice

abnormal leukocyte morphology ( J:88065 )

increased eosinophil cell number ( J:88065 )

• on days 24 and 30, ovalbumin-treated mice exhibit an increase in the bronchoalveolar lavage and lung tissue eosinophil numbers compared with similarly treated wild-type mice

increased lymphocyte cell number ( J:88065 )

• ovalbumin-treated mice exhibit an increase in the bronchoalveolar lavage and lung tissue lymphocyte numbers compared with similarly treated wild-type mice

increased T-helper 2 cell number ( J:88065 )

• on day 24, ovalbumin-treated mice exhibit an increased in Th2 helper cells in the bronchoalveolar lavage compared with similarly treated wild-type mice

increased macrophage cell number ( J:88065 )

• ovalbumin-treated mice exhibit an increase in the bronchoalveolar lavage and lung tissue macrophage cell numbers compared with similarly treated wild-type mice

increased monocyte cell number ( J:88065 )

• ovalbumin-treated mice exhibit an increase in the bronchoalveolar lavage and lung tissue monocyte numbers compared with similarly treated wild-type mice

increased IgE level ( J:88065 )

• ovalbumin-treated mice exhibit increased ovalbumin-IgE compared with similarly treated wild-type mice

cellular

increased T cell proliferation ( J:88065 )

• on day 24 hours in ovalbumin-treated wild-type mice compared with similarly treated wild-type mice

Genotype
MGI:4367696

hm12

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac

behavior/neurological

impaired contextual conditioning behavior ( J:105763 )

• when tested at 24 hours, mice exhibit reduced memory in hippocampus-dependent context conditioning compared with similarly treated wild-type mice

• however, mice tested at 30 hours for cued conditioning is normal

nervous system

reduced long-term potentiation ( J:105763 )

• long term potentiation is smaller in magnitude and shorter in duration than in wild-type mice

• however, mice exhibit normal NMDA receptor-dependent long term depression and paired pulse facilitation

Genotype
MGI:3652586

hm13

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6J

cardiovascular system

abnormal angiogenesis ( J:101783 )

• exhibit significantly reduced carotid artery intimal hyperplasia in response to vascular injury and fewer intimal smooth muscle cells

abnormal vascular smooth muscle physiology ( J:101783 )

• exhibit impairment of smooth muscle cell migration through a gelatin-coated membrane towards a chemoattractant and in a wound assay4

• isolated smooth muscle cells exhibit impaired ability to compact collagen gels, to assemble fibrillar collagen from exogenous monomers, and to attach to gelatin

muscle

abnormal vascular smooth muscle physiology ( J:101783 )

• exhibit impairment of smooth muscle cell migration through a gelatin-coated membrane towards a chemoattractant and in a wound assay4

• isolated smooth muscle cells exhibit impaired ability to compact collagen gels, to assemble fibrillar collagen from exogenous monomers, and to attach to gelatin

Genotype
MGI:4367273

hm14

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: involves: 129S6/SvEvTac * CD-1

mortality/aging

increased susceptibility to xenobiotic induced morbidity/mortality ( J:149957 )

• following myelodepletion with 5-fluorouracil (5-FU), 72% of mice die unlike similarly treated wild-type mice

hematopoietic system

abnormal megakaryocyte differentiation ( J:149957 )

• restoration of myeloid and megakaryotic lineages in 5-FU-treated mice is impaired compared to in similarly treated wild-type mice

impaired myelopoiesis ( J:149957 )

• restoration of myeloid and megakaryotic lineages in 5-FU-treated mice is impaired compared to in similarly treated wild-type mice

impaired hematopoiesis ( J:149957 )

• following myelodepletion with 5-fluorouracil (5-FU), mice exhibit delayed recovery compared with similarly treated wild-type mice

abnormal hematopoietic stem cell morphology ( J:149957 )

• following myelodepletion with 5-fluorouracil (5-FU), fewer hematopoietic stem cells enter S phase compared to in similarly treated wild-type mice

abnormal bone marrow cell physiology ( J:149957 )

• in transplantation experiments, chemokine-induced mobilization of bone marrow repopulating cells is impaired compared to in similarly treated wild-type mice

• mobilization of bone-marrow derived circulating endothelial cell progenitors is impaired compared to in similarly treated wild-type mice

homeostasis/metabolism

increased susceptibility to xenobiotic induced morbidity/mortality ( J:149957 )

• following myelodepletion with 5-fluorouracil (5-FU), 72% of mice die unlike similarly treated wild-type mice

decreased susceptibility to injury ( J:129161 )

• following optic nerve ligation, retinas fail to exhibit apoptosis unlike in similarly treated wild-type mice

decreased susceptibility to ischemic brain injury ( J:79535 )

• 24 hours following cerebral ischemia, mice exhibit reduced ischemic lesion volumes compared with similarly treated wild-type mice

• however, mice subjected to cerebral ischemia exhibit normal neurological deficits

nervous system

decreased susceptibility to ischemic brain injury ( J:79535 )

• 24 hours following cerebral ischemia, mice exhibit reduced ischemic lesion volumes compared with similarly treated wild-type mice

• however, mice subjected to cerebral ischemia exhibit normal neurological deficits

immune system

impaired myelopoiesis ( J:149957 )

• restoration of myeloid and megakaryotic lineages in 5-FU-treated mice is impaired compared to in similarly treated wild-type mice

vision/eye

abnormal retina apoptosis ( J:129161 )

• following optic nerve ligation, retinas fail to exhibit apoptosis unlike in similarly treated wild-type mice

cellular

abnormal retina apoptosis ( J:129161 )

• following optic nerve ligation, retinas fail to exhibit apoptosis unlike in similarly treated wild-type mice

abnormal megakaryocyte differentiation ( J:149957 )

• restoration of myeloid and megakaryotic lineages in 5-FU-treated mice is impaired compared to in similarly treated wild-type mice

Genotype
MGI:4367616

hm15

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: involves: 129S6/SvEvTac * FVB/N

nervous system

decreased neuron apoptosis ( J:96548 )

• wild-type neurons co-cultured with microglial cells exposed to TFN-alpha exhibit decreased cell death compared to neurons co-cultured with similarly treated wild-type microglial cells

homeostasis/metabolism

delayed wound healing ( J:150790 )

• at days 3, 5, and 7, mice exhibit delayed wound compared with similarly treated wild-type mice

cellular

decreased neuron apoptosis ( J:96548 )

• wild-type neurons co-cultured with microglial cells exposed to TFN-alpha exhibit decreased cell death compared to neurons co-cultured with similarly treated wild-type microglial cells

Genotype
MGI:4367735

cx16

• Allelic Composition: Dmd^mdx/Dmd^mdx; Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: B10.Cg-Mmp9^tm1Tvu Dmd^mdx

muscle

abnormal muscle morphology ( J:150030 )

♀ • mice exhibit improved muscle and sarcolemmal structure, more uniform fiber diameter, reduced inflammatory cell between adjacent fibers, and decreased necrosis and fibrosis compared with Dmd^mdx homozygotes

enhanced skeletal muscle regeneration ( J:150030 )

♀ • myofiber regeneration is increased compared to in Dmd^mdx homozygotes

immune system

decreased macrophage cell number ( J:150030 )

♀ • fewer macrophages accumulate in the muscles compared to in Dmd^mdx homozygotes

hematopoietic system

decreased macrophage cell number ( J:150030 )

♀ • fewer macrophages accumulate in the muscles compared to in Dmd^mdx homozygotes

Genotype
MGI:4367736

cx17

• Allelic Composition: Dmd^mdx/Dmd^mdx; Mmp9^tm1Tvu/Mmp9⁺
• Genetic Background: B10.Cg-Mmp9^tm1Tvu Dmd^mdx

muscle

abnormal muscle morphology ( J:150030 )

♀ • mice exhibit improved muscle and sarcolemmal structure, more uniform fiber diameter, reduced inflammatory cell between adjacent fibers, and decreased necrosis and fibrosis compared with Dmd^mdx homozygotes

abnormal muscle physiology ( J:150030 )

♀ • mice exhibit higher muscle force production compared with Dmd^mdx homozygotes

enhanced skeletal muscle regeneration ( J:150030 )

♀ • myofiber regeneration is increased compared to in Dmd^mdx homozygotes

immune system

decreased macrophage cell number ( J:150030 )

♀ • fewer macrophages accumulate in the muscles compared to in Dmd^mdx homozygotes

hematopoietic system

decreased macrophage cell number ( J:150030 )

♀ • fewer macrophages accumulate in the muscles compared to in Dmd^mdx homozygotes

Genotype
MGI:4365603

cx18

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu; Rag2^tm1Fwa/Rag2^tm1Fwa
• Genetic Background: B6.129S-Rag2^tm1Fwa Mmp9^tm1Tvu

neoplasm

decreased tumor incidence ( J:105098 )

• mice injected with A549 cells exhibit a reduction in the number of tumors that develop compared with similarly treated wild-type mice

• however, A549 cell tumor growth is normal

Genotype
MGI:4367346

cx19

• Allelic Composition: Mmp2^tm1Ito/Mmp2^tm1Ito; Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac

cardiovascular system

decreased susceptibility to induced choroidal neovascularization ( J:86805 )

• following laser trauma, mice exhibit decreased choroidal neovascularization compared with similarly treated single homozygote

vision/eye

decreased susceptibility to induced choroidal neovascularization ( J:86805 )

• following laser trauma, mice exhibit decreased choroidal neovascularization compared with similarly treated single homozygote

Genotype
MGI:4367614

cx20

• Allelic Composition: Apoe^tm1Unc/Apoe^tm1Unc; Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac

cardiovascular system

decreased susceptibility to atherosclerosis ( J:110044 )

• following temporary ligation, mice develop intimal atherosclerotic plaques with reduced volume, length, smooth muscle cells, and intraplaque foam cells and macrophages compared with similarly treated Apoe^tm1Unc homozygotes

vascular smooth muscle hypoplasia ( J:110044 )

• following temporary ligation, fewer smooth muscle cells are found in atherosclerotic plaques compared to in similarly treated Apoe^tm1Unc homozygotes

immune system

decreased macrophage cell number ( J:110044 )

• following temporary ligation, fewer foam cells and macrophages are found in atherosclerotic plaques compared to in similarly treated Apoe^tm1Unc homozygotes

muscle

vascular smooth muscle hypoplasia ( J:110044 )

• following temporary ligation, fewer smooth muscle cells are found in atherosclerotic plaques compared to in similarly treated Apoe^tm1Unc homozygotes

hematopoietic system

decreased macrophage cell number ( J:110044 )

• following temporary ligation, fewer foam cells and macrophages are found in atherosclerotic plaques compared to in similarly treated Apoe^tm1Unc homozygotes

Genotype
MGI:4367694

cx21

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu; Sftpd^tm1Jhf/Sftpd^tm1Jhf
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * FVB/N

respiratory system

overexpanded pulmonary alveolus ( J:121212 )

• as in Sftpd^tm1Jhf, mice exhibit enlarged alveolar spaces compared with wild-type mice with foamy macrophage and lymphocyte infiltrates

Genotype
MGI:4367710

cx22

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu; Rag2^tm1Fwa/Rag2^tm1Fwa
• Genetic Background: involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6 * FVB/N

neoplasm

decreased metastatic potential ( J:140033 )

• mice injected with tumor cells exhibit reduced lung tumor burden compared with similarly treated wild-type mice with reduced tumor size

abnormal tumor morphology ( J:140033 )

• metastatic lung tumors in mice injected with tumors cells exhibit decreased staining for blood vessels compared with equivalent tumors in wild-type mice

decreased tumor growth/size ( J:140033 )

• metastatic lung tumors in mice injected with tumors cells exhibit decreased size compared with tumors induced in similarly treated wild-type mice

Genotype
MGI:3510654

cx23

• Allelic Composition: Col4a3^tm1Jhm/Col4a3^tm1Jhm; Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ

immune system

glomerulonephritis ( J:63137 )

• double homozygotes exhibit no differences in the progression of glomerulonephritis compared with single Col4a3^tm1Jhm mutants, suggesting that MMP9 does not play a major role in the progression of Alport syndrome

renal/urinary system

glomerulonephritis ( J:63137 )

• double homozygotes exhibit no differences in the progression of glomerulonephritis compared with single Col4a3^tm1Jhm mutants, suggesting that MMP9 does not play a major role in the progression of Alport syndrome

abnormal renal glomerulus basement membrane morphology ( J:63137 )

• at 8 weeks, double homozygotes exhibit the characteristic splitting and thickening of the glomerular basement membrane observed in the Col4a3^tm1Jhm mouse model of Alport syndrome

increased renal glomerulus basement membrane thickness ( J:63137 )

• thickening of the glomerular basement membrane observed at 8 weeks

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
autosomal recessive Alport syndrome		DOID:0110033	OMIM:203780	J:63137

Genotype
MGI:3590209

cx24

• Allelic Composition: Hspg2^tm1Ref/Hspg2^tm1Ref; Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ

skeleton

increased diameter of humerus ( J:84739 )

short humerus ( J:84739 )

• short and thick

disorganized long bone epiphyseal plate ( J:84739 )

• severely disorganized

abnormal long bone metaphysis morphology ( J:84739 )

• greatly reduced

limbs/digits/tail

increased diameter of humerus ( J:84739 )

short humerus ( J:84739 )

• short and thick

Genotype
MGI:3522359

cx25

• Allelic Composition: Mmp13^tm1.1Werb/Mmp13^tm1.1Werb; Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: involves: 129S2/SvPas * 129S6/SvEvTac

growth/size/body

decreased body size ( J:94460 )

skeleton

abnormal long bone epiphyseal ossification zone morphology ( J:94460 )

• the front of ossification is similar to that seen in Mmp9 single homozygotes

abnormal long bone hypertrophic chondrocyte zone ( J:94460 )

• the normal columnar architecture is lost

increased width of hypertrophic chondrocyte zone ( J:94460 )

• seen in the long bones, more severe than in either single homozygote

abnormal bone marrow cavity morphology ( J:94460 )

• development of the bone marrow cavity is delayed

abnormal trabecular bone morphology ( J:94460 )

• decreased trabecular bone formation and abnormal growth plate development result in dramatically shortened skeletal elements

delayed bone ossification ( J:94460 )

• development of the secondary site of ossification is delayed

Genotype
MGI:3525489

cx26

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu; Timp1^tm1Pds/Timp1^tm1Pds
• Genetic Background: involves: 129S4/SvJae * 129S6/SvEvTac

immune system

immune system phenotype ( J:94836 )

♀N • double mutants are as susceptible to corneal bacterial infection as wild-type mice unlike Timp1 single homozygotes which show decreased susceptibility

Genotype
MGI:3652810

cx27

• Allelic Composition: Mmp12^tm1Sds/Mmp12^tm1Sds; Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: involves: 129S6/SvEvTac * 129X1/SvJ

nervous system

decreased oligodendrocyte number ( J:105765 )

• exhibit a decrease in the number of mature oligondendrocytes at P10, however no differences in oligodendrocyte precursor cell numbers

abnormal myelination ( J:105765 )

• exhibit a similar decrease in myelination in the corpus callosum at P7 and P10, but not at P14, as single homozygous mutants

cardiovascular system

decreased susceptibility to induced aneurysm formation ( J:62760 )

• following induction of aortic aneurysm with elastase, mice develop fewer aneurysms with less of an increase in aortic diameter compared with similarly treated wild-type mice

Genotype
MGI:3785292

cx28

• Allelic Composition: Mmp8^tm1Otin/Mmp8^tm1Otin; Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6

immune system

immune system phenotype ( J:113463 )

N • mice exhibit a normal local Shwartman response namely thrombohemorrhagic vasculitis

Genotype
MGI:4367704

cx29

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu; Tg(SOD1*G93A)1Gur/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * CD-1 * SJL

mortality/aging

mortality/aging ( J:141587 )

N • mice survive 31% longer than Tg(SOD1*G93A)1Gur mice

nervous system

nervous system phenotype ( J:141587 )

N • neuron loss observed in Tg(SOD1*G93A)1Gur mice is attenuated

immune system

decreased tumor necrosis factor secretion ( J:141587 )

• TNF-alpha staining is absent from neuronal cells in the spinal cord unlike in Tg(SOD1*G93A)1Gur mice

Genotype
MGI:4367274

cx30

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu; Tg(KRT14-HPV16)wt1Dh/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * FVB/N

neoplasm

increased skin squamous cell carcinoma incidence ( J:65699 )

• 27% of mice develop squamous cell carcinomas (SCCs) in the epidermis with more malignancy (increased aggressiveness and higher grade) compared to in Tg(KRT14-HPV16)wt1Dh mice

decreased tumor incidence ( J:65699 )

• mice exhibit fewer incidence of malignant conversions compared with Tg(KRT14-HPV16)wt1Dh mice

• 27% of mice develop squamous cell carcinomas (SCCs) in the epidermis compared to 50% of Tg(KRT14-HPV16)wt1Dh mice

• however, the numbers of SCCs per mouse is the same as in Tg(KRT14-HPV16)wt1Dh mice, and expression of the wild-type allele restores normal Tg(KRT14-HPV16)wt1Dh-induced neoplasia

integument

decreased keratinocyte proliferation ( J:65699 )

• compared to in Tg(KRT14-HPV16)wt1Dh mice

abnormal epidermal layer morphology ( J:65699 )

• at 2 months, all mice exhibit mild hyperplastic epidermis compared to in wild-type mice but not as severe as in Tg(KRT14-HPV16)wt1Dh mice

• at 4 months, 20% of mice develop epidermal dysplasia unlike in wild-type mice

• at 7 months, 90% of mice exhibit epidermal dysplasia unlike in wild-type mice

increased skin squamous cell carcinoma incidence ( J:65699 )

• 27% of mice develop squamous cell carcinomas (SCCs) in the epidermis with more malignancy (increased aggressiveness and higher grade) compared to in Tg(KRT14-HPV16)wt1Dh mice

cellular

decreased keratinocyte proliferation ( J:65699 )

• compared to in Tg(KRT14-HPV16)wt1Dh mice

Genotype
MGI:4367707

cx31

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:140033 )

• development of mammary gland tumors is similar to in Tg(MMTV-PyVT)634Mul mice

decreased metastatic potential ( J:140033 )

• Background Sensitivity: mice exhibit reduced lung metastasis compared with Tg(MMTV-PyVT)634Mul mice unlike on a background lacking C57BL/6 with an 80% reduction in surface tumor number, a 76% reduction in total tumor area, and a slight reduction in average tumor size

abnormal tumor morphology ( J:140033 )

• metastatic lung tumors exhibit decreased staining for blood vessels compared with equivalent tumors in Tg(MMTV-PyVT)634Mul mice

decreased tumor growth/size ( J:140033 )

• proliferation and apoptosis rates of metastatic tumor cells are decreased compared with cells from Tg(MMTV-PyVT)634Mul mice with the balance resulting in reduced tumor size

integument

increased mammary gland tumor incidence ( J:140033 )

• development of mammary gland tumors is similar to in Tg(MMTV-PyVT)634Mul mice

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:140033 )

• development of mammary gland tumors is similar to in Tg(MMTV-PyVT)634Mul mice

Genotype
MGI:4367723

cx32

• Allelic Composition: Mmp13^tm1Jdar/Mmp13^tm1Jdar; Mmp9^tm1Tvu/Mmp9^tm1Tvu
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6J * FVB/N

homeostasis/metabolism

delayed wound healing ( J:150790 )

• at days 3, 5, and 7, mice exhibit delayed wound closure with decreased vascular density at the wound compared with similarly treated wild-type mice

• during wound healing, mice exhibit reduced wound contraction and myofibroblast formation compared with similarly treated wild-type mice

• however, vascular density at the wound recovers by day 14

cellular

decreased cell proliferation ( J:150790 )

• in unstimulated or TGF-beta1-stimulated dermal fibroblasts compared with similarly treated wild-type fibroblasts

skeleton

abnormal epiphyseal plate morphology ( J:150790 )

growth/size/body

postnatal growth retardation ( J:150790 )

cardiovascular system

decreased angiogenesis ( J:150790 )

• vascular density is decreased at healing wounds compared to in similarly treated wild-type mice

Genotype
MGI:4367708

cx33

• Allelic Composition: Mmp9^tm1Tvu/Mmp9^tm1Tvu; Tg(MMTV-PyVT)634Mul/0
• Genetic Background: involves: 129S6/SvEvTac * FVB/N

neoplasm

increased mammary gland tumor incidence ( J:140033 )

• Background Sensitivity: development of mammary gland tumors and metastasis are similar to in Tg(MMTV-PyVT)634Mul mice unlike on a background containing C57BL/6

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:140033 )

• Background Sensitivity: development of mammary gland tumors and metastasis are similar to in Tg(MMTV-PyVT)634Mul mice unlike on a background containing C57BL/6

integument

increased mammary gland tumor incidence ( J:140033 )

• Background Sensitivity: development of mammary gland tumors and metastasis are similar to in Tg(MMTV-PyVT)634Mul mice unlike on a background containing C57BL/6